|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.0000 - 0.0000|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...